BioSyent (CVE:RX) Director Seyed Ahmad Ashrafi Sells 2,900 Shares of Company Stock

Key Points

• Director Seyed Ahmad Ashrafi sold 2,900 BioSyent shares at an average price of C$16.55, generating proceeds of C$47,995 and reducing his position by 11.9% to 21,461 shares.
• Ashrafi has made several additional sales recently, including 2,000 shares on September 22 and other transactions in September and June.
• BioSyent shares fell 2.1% to C$16.20, while the company’s market capitalization stood at approximately C$183.2 million.

BioSyent Inc. (CVE:RX - Get Free Report) Director Seyed Ahmad Ashrafi sold 2,900 shares of BioSyent stock in a transaction that occurred on Tuesday, September 22nd. The stock was sold at an average price of C$16.55, for a total value of C$47,995.00. Following the transaction, the director owned 21,461 shares in the company, valued at approximately C$355,179.55. The trade was a 11.90% decrease in their position.

Seyed Ahmad Ashrafi also recently made the following trade(s):

• On Monday, September 21st, Seyed Ahmad Ashrafi sold 300 shares of BioSyent stock. The shares were sold at an average price of C$16.05, for a total value of C$4,815.00.
• On Tuesday, September 22nd, Seyed Ahmad Ashrafi sold 700 shares of BioSyent stock. The shares were sold at an average price of C$16.20, for a total value of C$11,340.00.
• On Tuesday, September 22nd, Seyed Ahmad Ashrafi sold 1,000 shares of BioSyent stock. The stock was sold at an average price of C$16.75, for a total value of C$16,750.00.
• On Wednesday, September 2nd, Seyed Ahmad Ashrafi sold 100 shares of BioSyent stock. The stock was sold at an average price of C$16.00, for a total value of C$1,600.00.
• On Thursday, September 3rd, Seyed Ahmad Ashrafi sold 700 shares of BioSyent stock. The shares were sold at an average price of C$16.00, for a total transaction of C$11,200.00.
• On Tuesday, June 30th, Seyed Ahmad Ashrafi sold 1,884 shares of BioSyent stock. The shares were sold at an average price of C$14.65, for a total transaction of C$27,600.60.
• On Tuesday, June 30th, Seyed Ahmad Ashrafi sold 800 shares of BioSyent stock. The shares were sold at an average price of C$14.70, for a total transaction of C$11,760.00.
• On Tuesday, June 30th, Seyed Ahmad Ashrafi sold 600 shares of BioSyent stock. The stock was sold at an average price of C$14.50, for a total transaction of C$8,700.00.

BioSyent Trading Down 2.1%

RX stock traded down C$0.35 during trading on Friday, reaching C$16.20. 6,290 shares of the stock were exchanged, compared to its average volume of 8,279. The company has a current ratio of 2.07, a quick ratio of 6.91 and a debt-to-equity ratio of 6.85. The business has a 50 day moving average price of C$15.43 and a 200-day moving average price of C$14.85. BioSyent Inc. has a 1 year low of C$10.65 and a 1 year high of C$17.50. The firm has a market capitalization of C$183.21 million, a price-to-earnings ratio of 18.97 and a beta of 1.11.

BioSyent Company Profile

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.